AllianceBernstein’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-377,155
| Closed | -$119M | – | 3198 |
|
|
2023
Q4 | $119M | Buy |
377,155
+13,787
| +4% | +$2.68M | 0.05% | 350 |
|
|
2023
Q3 | $61.4M | Sell |
363,368
-20,594
| -5% | -$3.87M | 0.03% | 498 |
|
|
2023
Q2 | $83.3M | Sell |
383,962
-242,228
| -39% | -$51.9M | 0.03% | 446 |
|
|
2023
Q1 | $114M | Buy |
626,190
+42,808
| +7% | +$8.19M | 0.05% | 348 |
|
|
2022
Q4 | $115M | Buy |
583,382
+57,892
| +11% | +$12.4M | 0.05% | 342 |
|
|
2022
Q3 | $118M | Buy |
525,490
+398,898
| +315% | +$80.7M | 0.06% | 311 |
|
|
2022
Q2 | $16M | Buy |
126,592
+82,228
| +185% | +$9.45M | 0.01% | 941 |
|
|
2022
Q1 | $5.63M | Buy |
44,364
+100
| +0.2% | +$11.3K | ﹤0.01% | 1528 |
|
|
2021
Q4 | $5.8M | Hold |
44,264
| – | – | ﹤0.01% | 1538 |
|
|
2021
Q3 | $5.42M | Sell |
44,264
-2,130
| -5% | -$246K | ﹤0.01% | 1567 |
|
|
2021
Q2 | $5.29M | Buy |
46,394
+4,730
| +11% | +$553K | ﹤0.01% | 1582 |
|
|
2021
Q1 | $5.01M | Hold |
41,664
| – | – | ﹤0.01% | 1560 |
|
|
2020
Q4 | $4.23M | Buy |
41,664
+11,140
| +36% | +$1.03M | ﹤0.01% | 1592 |
|
|
2020
Q3 | $2.36M | Sell |
30,524
-2,459
| -7% | -$210K | ﹤0.01% | 1759 |
|
|
2020
Q2 | $3.68M | Buy |
32,983
+14,800
| +81% | +$1.29M | ﹤0.01% | 1497 |
|
|
2020
Q1 | $1.31M | Buy |
18,183
+9,543
| +110% | +$816K | ﹤0.01% | 1907 |
|
|
2019
Q4 | $651K | Buy |
+8,640
| New | +$378K | ﹤0.01% | 2439 |
|
Other funds holding KRTX
AllianceBernstein's KRTX Position: Q1 2024 in Review
AllianceBernstein sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 377,155 shares — an estimated $119M sold.
AllianceBernstein first reported a position in KRTX in Q4 2019 and held it in 17 quarters. The position peaked at $119M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.
- AllianceBernstein reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- AllianceBernstein sold 377,155 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $119M.
- AllianceBernstein first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 17 quarters.
- AllianceBernstein's Karuna Therapeutics, Inc. Common Stock position peaked at $119M in Q4 2023.
- 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.
Based on AllianceBernstein's 13F filing for Q1 2024, filed 14 May 2024.